---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071801"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:24:00.127966+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics prices $11M public offering of common stock and pre-funded warrants

## Summary
- Offering of 7,116,547 shares at $1.35/share and 1,031,602 pre-funded warrants at $1.3499 each.
- Gross proceeds of ~$11M; net proceeds of ~$10.1M after discounts and expenses.
- Proceeds to fund clinical development of GT-02287 for GBA1 Parkinson's disease.
- Underwriter Titan Partners granted 30-day option for 1,222,222 additional shares (15% over-allotment).
- Underwriter warrants for 570,370 shares at $1.6875, exercisable 6 months post-closing.

## SEC filing metadata
- accession: 0001104659-24-071801
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924071801/0001104659-24-071801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924071801/tm2416858d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071801
- JSON: https://secwatch.observer/filing/0001104659-24-071801.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.